


## **IN THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **LISTING OF THE CLAIMS:**

1.-33. (Cancelled)


34. (Previously Presented) A method for treating cell proliferative disorders caused by and/or associated with an altered cell cycle dependent kinase activity, by administering to a mammal in need thereof an effective amount of a pyrazolo derivative represented by formula (Ia)



wherein

R is a  $-\text{COR}^a$  group, wherein  $\text{R}^a$  is hydrogen or an optionally substituted group selected from straight or branched  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_3\text{-C}_6$  cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl;

$\text{R}_1$  is a group of formula (IIa)



wherein the cycle represents a 5 to 7 membered heterocyclic ring, wherein X, directly linked to the rest of the molecule, represents a carbon or nitrogen atom; Y is a carbon, nitrogen, oxygen or

sulfur atom or it is an NH group, provided that at least one of X and Y is other than a carbon atom; R<sup>c</sup> is, independently from each other and in any one of the free positions of the heterocyclic ring of formula (IIa), an optionally substituted group selected from straight or branched C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl, arylalkyl, heterocyclyl, heterocyclalkyl, amino, aminocarbonyl, carboxy, oxo (=O), alkoxy carbonyl, alkylcarbonyl or arylcarbonyl; and n is 0 or an integer from 1 to 4;

or a pharmaceutically acceptable salt thereof.

35. (Previously Presented) The method according to claim 34 wherein the cell proliferative disorder is selected from the group consisting of cancer, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.

36. (Previously Presented) The method according to claim 35 wherein the cancer is selected from the group consisting of carcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system, melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer, and Kaposi's sarcoma.

37. (Previously Presented) The method according to claim 34 wherein the cell proliferative disorder is selected from the group consisting of benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-surgical stenosis and restenosis.

38. (Previously Presented) The method according to claim 34 which provides tumor angiogenesis and metastasis inhibition.

39. (Previously Presented) The method according to claim 34 which provides organ transplant rejection and host versus graft disease treatments.


40. (Previously Presented) The method according to claim 34 which provides treatment or prevention of radiotherapy-induced or chemotherapy-induced alopecia.

41. (Previously Presented) The method according to claim 34 further comprising subjecting the mammal in need thereof to a radiation therapy or chemotherapy regimen in combination with at least one cytostatic or cytotoxic agent.

42. (Previously Presented) The method according to claim 34 wherein the mammal in need thereof is a human.

43. (Previously Presented) A method for inhibiting cyclin dependent kinase activity which comprises contacting the said kinase with an effective amount of a compound as defined in claim 34.


44. (Previously Presented) A compound of formula (Ia)



wherein


R is a  $-\text{COR}^a$  group, wherein  $\text{R}^a$  is hydrogen or an optionally substituted group selected from straight or branched  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_3\text{-C}_6$  cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl;

$\text{R}_1$  is a group of formula (IIa)




wherein the cycle represents a 5 to 7 membered heterocyclic ring, wherein X, directly linked to the rest of the molecule, represents a carbon or nitrogen atom; Y is a carbon, nitrogen, oxygen or sulfur atom or it is an NH group, provided that at least one of X and Y is other than a carbon atom;  $\text{R}^c$  is, independently from each other and in any one of the free positions of the heterocyclic ring of formula (IIa), an optionally substituted group selected from straight or branched  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_3\text{-C}_6$  cycloalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, amino, aminocarbonyl, carboxy, oxo ( $=\text{O}$ ), alkoxy carbonyl, alkylcarbonyl or arylcarbonyl; and n is 0 or an integer from 1 to 4;  
or a pharmaceutically acceptable salt thereof.

45. (Previously Presented) A compound of formula (Ia) according to claim 44 wherein  $\text{R}_1$  is a group of formula (IIa) selected from:



wherein R, n and  $\text{R}^c$  are as defined in claim 44.

46. (Previously Presented) A compound of formula (Ia) according to claim 44 wherein R<sub>1</sub> is a group of formula (IIa) selected from:



wherein R, n and R<sup>c</sup> are as defined in claim 44.

47. (Previously Presented) A compound, optionally in the form of a pharmaceutically acceptable salt, selected from the group consisting of:

N-{6,6-dimethyl-5-[(2R)-tetrahydrofuran-2-ylcarbonyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-4-fluorobenzamide,

N-{6,6-dimethyl-5-[(2S)-tetrahydrofuran-2-ylcarbonyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-4-fluorobenzamide,

N-{6,6-dimethyl-5-[(1-methylpiperidin-4-yl)carbonyl]-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-cyclobutanebenzamide,

N-{6,6-dimethyl-5-[(1-methylpiperidin-4-yl)carbonyl]-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-4-fluorobenzamide,

N-{6,6-dimethyl-5-[(4-methylpiperazin-1-yl)carbonyl]-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-4-fluorobenzamide,

3-methyl-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazole-3-yl]-butanamide, and

4-Chloro-N-[6,6-dimethyl-5-(4-pyrrolidin-1-yl-methyl-piperidine-1-carbonyl)-1,4,5,6-tetrahydro-pyrrolo[3,4-c]pyrazol-3-yl]-benzamide;

or a pharmaceutically acceptable salt thereof.

48. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, as defined in claim 44, and at least one pharmaceutically acceptable excipient, carrier and/or diluent.

49. (Currently Amended) A pharmaceutical composition according to claim 48 further comprising ~~one or more~~ a chemotherapeutic agents agent selected from the group consisting of cytostatic or cytotoxic agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, cyclooxygenase inhibitors, matrixmetalloprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-grow factor receptor agents, anti-HER agents, anti-EGFR agents, anti-angiogenesis agents, farnesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, cell cycle inhibitors, cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors and mixtures thereof.

50. (Currently Amended) A product or kit comprising a compound of formula (Ia) as defined in claim 44 or a pharmaceutical composition thereof as defined in claim 48, and ~~one or more~~ a chemotherapeutic agents agent selected from the group consisting of cytostatic or cytotoxic agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, cyclooxygenase inhibitors, matrixmetalloprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-grow factor receptor agents, anti-HER agents, anti-EGFR agents, anti-angiogenesis agents, farnesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, cell cycle inhibitors, cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors and mixtures thereof, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.